All News NovaBay Pharmaceuticals, Inc.

Equities

NBY

US66987P4090

Market Closed - Nyse Other stock markets 21:00:00 14/06/2024 BST			5-day change	1st Jan Change
2.51 ^USD	-2.33%		-7.38%	-64.85%

05-09	NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-09	Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American	06-07	BU
Reverse Split: 1 of 35	05-30	FA
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates	05-29	BU
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms	05-13	BU
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M	05-09	MT
Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results	05-09	BU
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon	05-07	BU
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024	05-06	AQ
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024	05-03	BU
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales	04-22	BU
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity	04-19	BU
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses	04-17	BU
Transcript : NovaBay Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 26, 2024	03-26
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-26	CI
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M	03-26	MT
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results	03-26	BU
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-26	CI
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K	03-26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News NovaBay Pharmaceuticals, Inc.

Equities

NBY

US66987P4090

All News

Filters